Cancer antigen 125

From Libre Pathology
(Redirected from CA-125)
Jump to navigation Jump to search

Cancer antigen 125, abbreviated CA125 and CA-125, is a common immunostain and serum marker of disease. It is also known as mucin 16 and officially abbreviated MUC16.[1][2]

It is elevated in the serum in ovarian cancer and mildly or moderately elevated in endometriosis.

Positive

Positive/negative

Usually negative

See also

References

  1. Online 'Mendelian Inheritance in Man' (OMIM) 606154
  2. URL: http://www.ncbi.nlm.nih.gov/gene/94025. Accessed on: 3 August 2016.
  3. 3.0 3.1 3.2 Tornos, C.; Soslow, R.; Chen, S.; Akram, M.; Hummer, AJ.; Abu-Rustum, N.; Norton, L.; Tan, LK. (Nov 2005). "Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.". Am J Surg Pathol 29 (11): 1482-9. PMID 16224215.
  4. Jiang, K.; Tan, E.; Sayegh, Z.; Centeno, B.; Malafa, M.; Coppola, D. (Apr 2016). "Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.". Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000368. PMID 27093451.
  5. Lee, HI.; Kang, KH.; Cho, YM.; Lee, OJ.; Ro, JY. (Jun 2006). "Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity.". Arch Pathol Lab Med 130 (6): 871-4. doi:10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2. PMID 16740043.
  6. Cheng X, Gou HF, Liu JY, Luo DY, Qiu M (2016). "Clinical significance of serum CA125 in diffuse malignant mesothelioma". Springerplus 5: 368. doi:10.1186/s40064-016-1998-7. PMC 4805673. PMID 27066377. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805673/.
  7. Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A (January 1997). "Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression". Histopathology 30 (1): 49–56. doi:10.1046/j.1365-2559.1996.d01-562.x. PMID 9023557.
  8. Higashi, M.; Yamada, N.; Yokoyama, S.; Kitamoto, S.; Tabata, K.; Koriyama, C.; Batra, SK.; Yonezawa, S. (2012). "Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type.". Pathobiology 79 (2): 101-6. doi:10.1159/000335164. PMID 22286058.